- Home
- PERF vs DSGN Comparison
PERF vs DSGN Comparison
Compare PERF & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PERF
- DSGN
- Stock Information
- Founded
- PERF 2015
- DSGN 2017
- Country
- PERF Taiwan
- DSGN United States
- Employees
- PERF N/A
- DSGN N/A
- Industry
- PERF Computer Software: Prepackaged Software
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- PERF Technology
- DSGN Health Care
- Exchange
- PERF Nasdaq
- DSGN Nasdaq
- Market Cap
- PERF 191.5M
- DSGN 208.9M
- IPO Year
- PERF N/A
- DSGN 2021
- Fundamental
- Price
- PERF $2.00
- DSGN $5.86
- Analyst Decision
- PERF Buy
- DSGN
- Analyst Count
- PERF 1
- DSGN 0
- Target Price
- PERF $5.00
- DSGN N/A
- AVG Volume (30 Days)
- PERF 145.1K
- DSGN 167.2K
- Earning Date
- PERF 10-28-2025
- DSGN 11-06-2025
- Dividend Yield
- PERF N/A
- DSGN N/A
- EPS Growth
- PERF 4.30
- DSGN N/A
- EPS
- PERF 0.06
- DSGN N/A
- Revenue
- PERF $64,369,000.00
- DSGN N/A
- Revenue This Year
- PERF $15.84
- DSGN N/A
- Revenue Next Year
- PERF $14.54
- DSGN N/A
- P/E Ratio
- PERF $33.23
- DSGN N/A
- Revenue Growth
- PERF 13.19
- DSGN N/A
- 52 Week Low
- PERF $1.51
- DSGN $2.60
- 52 Week High
- PERF $3.44
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- PERF 49.90
- DSGN 55.34
- Support Level
- PERF $1.88
- DSGN $5.65
- Resistance Level
- PERF $1.97
- DSGN $6.65
- Average True Range (ATR)
- PERF 0.08
- DSGN 0.51
- MACD
- PERF 0.01
- DSGN -0.03
- Stochastic Oscillator
- PERF 46.77
- DSGN 54.43
About PERF Perfect Corp.
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions. The company runs a hybrid business model of direct consumer business (B2C business) and enterprise business (B2B business). For B2C businesses, the company offers six mobile apps under the "YouCam" suite, along with one online editing service tool, YouCam Online Editor, featuring AI and AR technologies. For B2B businesses, the company offers AI and AR-powered solutions tailored for the beauty and fashion industry. Geographically, the company has a presence in the United States, Americas-other, France, Japan, and Others. The company generates the majority of its revenue from the United States.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.